NASDAQ:ANGO - AngioDynamics Stock Price, Forecast & News

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Thursday, October, 3rd. The medical instruments supplier reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.04. The medical instruments supplier earned $66 million during the quarter, compared to analyst estimates of $67.74 million. AngioDynamics had a net margin of 17.79% and a return on equity of 4.89%. The firm's revenue for the quarter was up 3.3% on a year-over-year basis. During the same quarter last year, the business posted $0.16 EPS. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Friday, January 3rd 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics updated its FY20 earnings guidance on Thursday, October, 3rd. The company provided EPS guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $281.89 million.

2 brokerages have issued 12-month price objectives for AngioDynamics' stock. Their forecasts range from $21.00 to $23.00. On average, they expect AngioDynamics' stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 43.0% from the stock's current price. View Analyst Price Targets for AngioDynamics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

News articles about ANGO stock have been trending somewhat positive recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AngioDynamics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for AngioDynamics.

AngioDynamics saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 748,500 shares, a decline of 7.9% from the October 31st total of 812,500 shares. Based on an average daily trading volume, of 267,200 shares, the days-to-cover ratio is currently 2.8 days. Approximately 2.0% of the shares of the company are sold short. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Oasis Petroleum (OAS), Intel (INTC), General Electric (GE), FireEye (FEYE), Mattel (MAT), Hanesbrands (HBI), Marathon Oil (MRO), Bank of America (BAC), Chesapeake Energy (CHK) and Centurylink (CTL).

AngioDynamics' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (3.69%), Tributary Capital Management LLC (1.80%), Fenimore Asset Management Inc. (1.52%), Granahan Investment Management Inc. MA (1.11%), Systematic Financial Management LP (1.09%) and Foundry Partners LLC (0.65%). Company insiders that own AngioDynamics stock include James C Clemmer, Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Man Group plc, Tributary Capital Management LLC, Barclays PLC, Foundry Partners LLC, State Street Corp and Keybank National Association OH. View Insider Buying and Selling for AngioDynamics.

ANGO stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Mackay Shields LLC, Assenagon Asset Management S.A., Boston Advisors LLC, Systematic Financial Management LP, Granahan Investment Management Inc. MA, Tibra Equities Europe Ltd and Meeder Asset Management Inc.. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $15.38.

AngioDynamics has a market capitalization of $578.60 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]